Related by context. All words. (Click for frequent words.) 79 next generation URAT1 71 leading oral taxane 70 oral picoplatin 70 CD# CEA 70 XL# anticancer compounds 70 candidate REP# 69 oral prodrug 69 MCSP respectively 69 R#/MEM # 69 Solazed TM 69 Trofex TM 69 PEG SN# 68 VEGFR2 inhibitor 68 PSMA ADC 68 recombinant PSMA vaccine 68 MKC# MT 68 GVAX ® 68 dimebon latrepirdine 68 AAG geldanamycin analog 68 MKC# 68 Phase #b/#a clinical 68 including eniluracil ADH 68 tubulin inhibitor 67 GLP toxicology studies 67 Trofex 67 oral proteasome inhibitor 67 Phase Ib study 67 IMPDH inhibitor 67 TRIOLEX ™ 67 mGluR2 NAM 67 Panzem R 67 pharmacogenomic translational research 67 PORxin TM platforms 67 oncolytic virus therapies 67 Phase 2a clinical trials 67 PNP inhibitor 67 clinical trials Archexin 67 GVAX R 67 RAS MAPK pathway 67 FOLOTYN ® 67 Phase lll 67 sapacitabine CYC# 67 Completes Patient Enrollment 66 HepeX B TM 66 OvaRex R 66 Archexin 66 TKM PLK1 66 TBC# 66 includes TOLAMBA TM 66 rxRNA 66 novel VDA molecule 66 pralatrexate injection folate analogue 66 Cloretazine ® 66 Phase 2b Clinical Trial 66 Fx #A 66 PANVAC VF 66 ALTROPANE R 66 Trofex ™ 66 TOCOSOL Camptothecin 66 seliciclib CYC# 66 solid tumors ZYBRESTAT 66 CRLX# 66 product TNFerade TM 66 Solazed 66 apricitabine ATC 66 alvespimycin 66 mertansine 66 TELINTRA R 66 candidate CRLX# 66 Empatic ™ 66 initiated Phase Ib 65 HDL Mimetic Peptide 65 vivo preclinical 65 trastuzumab DM1 T DM1 65 huC# DM4 65 selective androgen receptor modulator 65 delta opioid receptor 65 IMA# 65 RenaZorb TM 65 Personalized Immunotherapy 65 hypoxia activated prodrug 65 Zemiva TM 65 THR beta agonist 65 non nucleoside inhibitor 65 Daclizumab 65 Trastuzumab DM1 65 oral ghrelin agonist 65 Phase III ADT 65 telomerase inhibitor drug 65 hyaluronidase enzyme 65 TNFerade ™ 65 Phase #/#a trial 65 novel therapeutic antibodies 65 Phase 1b clinical trials 65 Hedgehog Pathway Inhibitor 65 ALS #-# 65 telomerase therapeutic 65 JAK#/JAK# inhibitor CYT# 65 compound INCB# 65 Xcytrin R 65 targeted radiotherapeutic 65 Acetavance TM intravenous acetaminophen 65 Reports Preclinical Data 65 MKC# MKC# PP 65 Exherin TM 65 Presents Preclinical Data 65 Phase Ib II 65 Telik logo TELINTRA 65 Tarvacin Anti Cancer 65 Initiates Clinical 65 ENMD # 65 Lisofylline LSF 65 orally administered inhibitor 65 confirmatory Phase 3 65 novel L DOS# 65 CCR9 antagonist 65 Azedra ™ 65 Crofelemer budesonide foam 65 CEQ# 65 Initiates Enrollment 64 Miraxion Amarin lead 64 evaluating mipomersen 64 oral nucleoside analogue 64 ABL inhibitor 64 Azedra TM 64 KNS # 64 Phase Ib IIa 64 topical antifungal product 64 ThermoDox ® clinical 64 CYT# potent vascular disrupting 64 Zalypsis 64 mGluR5 NAM 64 personalized cellular immunotherapy 64 CCR5 mAb 64 developing ostarine selective 64 product platforms AZX# 64 ospemifene 64 Selective Electrochemical Tumor Ablation 64 Elagolix 64 PDE4 inhibitor 64 Allovectin 7 R 64 ELND-#/AZD-# 64 Presents Positive 64 CCX# 64 IND submission 64 candidate AQ4N 64 Perflubutane Polymer Microspheres 64 SUCCEED trial 64 nucleoside tide 64 IMiDs ® 64 XP# XP# 64 cancer indications bafetinib 64 Panzem R NCD 64 MAXY VII 64 GATTEX ™ 64 AKIP ™ 64 lintuzumab SGN 64 anticoagulant reversing agent 64 LymphoStat B TM 64 PORxin TM 64 pentadentate logo R 64 Presents Preclinical 64 PDX pralatrexate 64 HuMax CD#b 64 orally dosed 64 Phase IIa trials 64 non nucleoside HCV 64 R roscovitine 64 Zemiva ™ 64 Protexia ® 64 Tesetaxel 64 Quinamed 64 TRIOLEX TM HE# 64 ZFP Therapeutics 64 rALLy trial 64 Phase 2b Trial 64 GALNS 64 website http:/www.molecularinsight.com 64 stage antibody MT# 64 Pimavanserin 64 TKM ApoB 64 Hematide TM 64 6 sulfatase 64 romidepsin novel 64 compound AEOL # 64 PLK1 SNALP 64 Initiates Phase II 64 urocortin 2 64 IL# PE#QQR 63 Omacetaxine 63 SinuNase ™ 63 metaglidasen 63 thrombin component 63 forodesine 63 TKB# 63 recombinant biopharmaceutical 63 Pruvel TM 63 novel trazodone formulation 63 Ceragenin ™ 63 Romidepsin 63 PGL# 63 gastro intestinal inflammation 63 candidates Azedra 63 Androxal TM 63 Phase 1a clinical 63 ApoB SNALP 63 Initiate Clinical Trial 63 R MSCRAMM 63 Hematide ™ 63 Begins Dosing 63 Genasense ® oblimersen 63 lead Aganocide compound 63 Prodarsan R 63 SCIB1 63 NU# direct 63 ALN PCS 63 rALLy clinical trial 63 AFREZZA TM 63 generation purine nucleoside 63 antiangiogenic activity 63 Nicotine Conjugate Vaccine 63 GALNS N acetylgalactosamine 63 BLA filing 63 Inc. www.micromet inc.com 63 Dyax logo 63 CR# vcMMAE 63 EGS# 63 Evoltra ® 63 CB2 selective receptor agonist 63 registrational trial 63 Hsp# Inhibitor 63 tramiprosate Alzhemed TM 63 AMD# [002] 63 phenylalanine ammonia lyase 63 Neo Kidney Augment 63 nasal decolonization 63 P#X# antagonist 63 lead molecular radiotherapeutic 63 Angiocept 63 include Ischemic Paraplegia 63 TRIOLEX HE# 63 delivery polymer matrix 63 Initiates Clinical Trial 63 signal detection CTSD 63 non porcine pancreatic 63 Phase IIa clinical trials 63 RGB # 63 Veronate R 63 phase IIa clinical 63 HEPLISAV TM hepatitis B 63 TMC# [002] 63 initiate multicenter 63 rALLy 63 serine protease inhibitor CU# 63 MEK inhibitor RDEA# 63 inflammatory autoimmune diseases 63 budesonide foam 63 Safinamide 63 Curaxin 63 MediGene focuses 63 Oncotype DX colon cancer 63 commercialize CorMedix drug 63 CRMD# 63 BiTE R 63 diabetes irritable bowel 63 Bioral Amphotericin B 63 PEGylated interferon 63 ONCONASE R 63 eTag assays 63 vidofludimus 63 candidate TNFerade biologic 63 HDL Selective Delipidation 63 acyclovir Lauriad R 63 2 inhibitor CYT# 63 evaluating tivozanib 63 EXPLORE Xa 63 Locteron ® 63 Phase III Pivotal 63 molecular imaging radiopharmaceuticals 63 Kimchee Kronicles 63 acetylgalactosamine 6 63 Oral Calcitonin 63 PEGylated irinotecan 63 please visit www.advaxis.com 63 INCB# [001] 63 PI3K/Akt pathway inhibitor 63 HuMax TAC 63 SinuNase TM 63 novel antimitotic agent 63 aldehyde dehydrogenase ALDH2 deficiency 63 IMiDs R 63 PROSTASCINT R 63 Exelixis compounds 63 omacetaxine mepesuccinate 63 YONDELIS 63 MVA BN R 63 Virulizin ® 63 Alfacell proprietary ribonuclease 63 Budesonide foam crofelemer 62 product candidate Lpathomab 62 generation proteasome inhibitor 62 preclinically 62 immunotherapeutic approaches 62 Curaxin CBLC# 62 systemic RNAi therapeutic 62 International LAB Pharma 62 JAK2 Inhibitor 62 evaluating bafetinib 62 CORT # 62 Anavex #-# 62 omega interferon 62 NurOwn 62 Phase IIb clinical trials 62 HCV nucleotide polymerase inhibitor 62 Canvaxin TM 62 TransVax 62 REVIVE Diabetes 62 Aganocide 62 Successfully Completes Phase 62 rindopepimut 62 NuroPro R 62 candidate XP# 62 using VIAdel TM 62 MAA submission 62 Chimigen TM 62 Neo Kidney Augment ™ 62 XL# XL# XL# XL# 62 generation NNRTI 62 Panzem NCD 62 CTAP# Capsules 62 kidney urologic 62 orally inhaled migraine 62 investigational pan BCR 62 ionotropic glutamate receptor antagonists 62 HIV RDEA# 62 Pharmos pipeline 62 R sorafenib tablets 62 individualized cellular immunotherapy 62 phase IIb study 62 MT#/MEDI-# 62 huN# DM1 62 maximally tolerated dose 62 ALN TTR 62 LE SN# 62 Optiquel ™ 62 Pivotal Phase III 62 LymphoStat B belimumab 62 HEPLISAV ™ 62 IIa clinical 62 GATTEX TM 62 molecular chaperone regulation 62 Aplidin R 62 Bayer HealthCare Onyx Pharmaceuticals 62 HCD# [002] 62 Vitaxin 62 oral opioid modulator 62 malignant mesothelioma Alfacell 62 Empatic TM 62 2 methoxyestradiol 62 Nanobody R 62 recurrent metastatic ovarian cancer 62 Syncria albiglutide 62 candidate Trofex TM 62 Xcellerated T Cells 62 PSN# [002] 62 DOS# 62 Onalta ™ 62 MAGE A3 ASCI 62 Panzem 62 RNAi Therapeutic 62 HGS ETR1 62 Vicriviroc 62 sarcoma melanoma 62 Clinical Trial Results 62 Completes Enrollment 62 Hedgehog pathway inhibitor 62 Aurora kinase inhibitor 62 Bezielle 62 XL# XL# 62 antibody MAb 62 therapeutic monoclonal antibody 62 Commences Phase 62 markets HP Acthar 62 TransVax TM 62 DEB# 62 Oracea TM 62 European Sepsis Trial 62 Symadex 62 www.polymedix.com 62 small molecule defensin 62 Aurexis 62 4SC AG ISIN DE# 62 ongoing Phase IIIb 62 Ostabolin C TM 62 BRIM3 62 Pivotal Phase 62 blood serum biomarkers 62 midstage clinical 62 CRD5 62 romazarit 62 ALN VSP 62 cannabinor 62 Phase III Clinical Trial 62 XOMA 3AB 62 generation PNP inhibitor 62 Phase IIb trials 62 Mipomersen 62 Achieves Primary Endpoint 62 SIRT1 activators 62 virus HCV protease inhibitor 62 transgenically produced product 62 Xanafide 62 tiapamil 62 preclinical pharmacokinetic 62 mGluR5 negative 62 cMET 62 candidates Azedra TM 62 refractory chronic lymphocytic 62 Files IND 62 subsidiaries visit http:/www.apricusbio.com 62 CAPACITY trials 62 muscarinic receptor agonist 62 Kosan dependence 62 website http:/www.celsion.com 62 TransVax ™ 62 HCV RNA polymerase 62 Combination REOLYSIN R 62 adecatumumab MT# 62 RhuDex TM 62 Iluvien ® 62 JZP 62 SNALP technology 62 albiglutide 62 AIMM trial 62 L Annamycin 62 proprietary intranasal insulin 61 GATTEX ® 61 LibiGel ® testosterone gel 61 Topline Results 61 AEG# 61 INSPIRE Trial Phase III 61 website www.celsion.com 61 phase IIb clinical 61 programs visit http:/www.bionovo.com 61 oral gallium 61 Aeolus Pharmaceuticals Announces 61 systemic Phase 1b 61 novel emulsion formulation 61 preclinical efficacy 61 angiotensin analog 61 Phase 2a Trial 61 molecular imaging radiopharmaceutical 61 VitiGam 61 PMX # heptagonist 61 Metastatic Melanoma 61 IMC #B 61 developed preclinically 61 aplindore 61 MAXY alpha 61 Bioral R 61 HGS ETR2 61 Oral NKTR 61 deforolimus 61 DGAT1 inhibitors 61 markets Testim ® 61 TransVax tm 61 novel peptides 61 EndoTAG TM -1 61 Nasulin ™ 61 APEX PD 61 Azedra 61 TOCOSOL Paclitaxel 61 Adnectin 61 MEK Inhibitor 61 oral dihydropyrimidine dehydrogenase DPD 61 Tumour Vascular Disrupting Agent 61 selectin antagonist 61 please visit http:/www.sunesis.com 61 mitotic kinesins 61 Vaxfectin R formulated 61 proprietary BiTE ® 61 Pertuzumab 61 pan BCR ABL 61 systemically administered 61 generation rotary VAD 61 Novel Antibody 61 Bavituximab 61 SAR# [002] 61 nucleotide analog 61 dosing cohort 61 palifosfamide Zymafos TM 61 Clevudine 61 polysaccharide polymer 61 Shigamabs ® 61 Provectus Pharmaceuticals specializes 61 tezampanel NGX# 61 XL# XL# XL# 61 Plicera 61 Surfaxin LS 61 Allovectin 7 r 61 PROVENGE ® 61 RANK Ligand inhibitor 61 sorafenib tablets 61 successfully commercialize Iluvien 61 Phase 2a Clinical Trial 61 TRO# 61 sodium Injection 61 developing ACAPODENE 61 oral taxane 61 AKT inhibitor 61 pharmacokinetic PK study 61 vaccine RiVax TM 61 HuLuc# 61 Aganocide ® 61 investigational humanized monoclonal antibody 61 drug pipeline TAFA# 61 Submits IND 61 omecamtiv mecarbil formerly 61 accumulate preferentially 61 BHT DNA 61 Spiegelmer ® 61 PEG PAL PEGylated recombinant 61 Initiates Phase III 61 ZEVALIN ® 61 TM Aganocide 61 novel oral anticoagulant 61 Tesmilifene 61 forodesine hydrochloride 61 human IgG1 monoclonal 61 Alzhemed TM 61 Meets Primary Endpoint 61 EndoTAG TM 61 liposomal formulation 61 candidate deforolimus 61 Marqibo TM 61 oral isotype selective HDAC 61 OTC BB PVCT http:/www.pvct.com 61 Phase Ib clinical trials 61 Alocrest 61 SMT C# 61 ragweed allergy immunotherapeutic 61 Troxatyl 61 TASKi2 61 orBec R oral beclomethasone 61 RhuDex ® 61 INTEGRILIN R eptifibatide Injection 61 SynCon 61 BiovaxID TM 61 Phase IIb Trial 61 hepatitis C polymerase inhibitor 61 Serdaxin ® 61 torezolid phosphate 61 Inc Therapeutic Competitors 61 Initiate Phase 61 NS5b 61 DIRECT Trial 61 highly purified pasteurized 61 potent suppressor 61 Annamycin 61 Naglazyme R 61 Myocet 61 toenail onychomycosis 61 drug GAP #B# 61 NOX E# 61 ChronVac C R 61 Phase 1b trial 61 Pharmos proprietary 61 ALN HTT 61 regarding Aethlon Medical 61 Biopharmaceuticals AG 61 agonistic human 61 ArQule Kinase Inhibitor Platform 61 LEAPS TM 61 hypoxia selective 61 include PLX IBD 61 IMiDs 61 Phase IIb Clinical Trial 61 GRN# 61 SILENOR 61 ularitide 61 SAR# [004] 61 TÎ ² 4 61 glucokinase activator 61 modified glutathione analog 61 PDE# inhibitors 61 relapsed leukemia 61 biologic therapeutics 61 RECOTHROM R 61 inhibit metastasis 61 Quinamed R 61 Capesaris 61 Files Investigational 61 Voreloxin 61 Vicinium TM 61 Intravenous CP 61 Nasdaq PPHM 61 DNA methyltransferase inhibitors 61 OMP #M# 61 Atiprimod 61 GRNVAC1 61 DPX Survivac 61 phase Ib 61 HCV polymerase 61 CA9 SCAN 61 TACI Ig 61 clinical trials Archexin ® 61 AeroLEF R 61 JAK inhibitors 61 phase IIa 61 Exherin 61 Hedgehog antagonist 61 HCV polymerase inhibitors 61 Phase #b/#a trial 61 novel orally inhaled 61 ImmunoVEX HSV2 61 DURECT proprietary 61 Inc. NASDAQ IDIX 61 midstage trials 61 Ocrelizumab 61 non nucleoside polymerase 61 TRIOLEX HE# APOPTONE HE# 61 LHRH antagonists 61 lorvotuzumab mertansine 61 Allovectin 7 61 include GALNS N 61 ATRA IV 61 Ophena TM 60 Phase IIa trial 60 ANCHOR trial 60 Chaim Lebovits President 60 PROSTVAC TM 60 generation Hsp# inhibitor 60 novel histone deacetylase 60 anti amnesic 60 Albuferon albinterferon alfa 2b 60 AMPK activators 60 treats acute lymphoblastic 60 MEND CABG II 60 autologous cellular immunotherapy 60 trial evaluating PRX# 60 include VALSTAR TM 60 products MKC# PP 60 ASONEP TM 60 isoform selective 60 PRT# 60 INTERCEPT red 60 BLA submission 60 Homspera ® 60 YOUR LOCAL ANIMAL SHELTER 60 imetelstat GRN#L 60 XmAb ® 60 FluCide 60 Dyloject TM 60 3 registrational trial 60 Factor VIIa 60 ongoing Phase 1b 60 StaphVAX R 60 Entereg R 60 anti botulism antibody 60 HQK 60 interferon gamma 1b 60 Testosterone MDTS ® 60 receptor tyrosine kinase inhibitor 60 RECORD1 60 OXi# 60 www.vioquestpharm.com 60 favorable pharmacokinetic profile 60 Memryte 60 Advaxis Phase 60 ARRY # 60 PD LID 60 CHAMPION PCI 60 PEGylated Fab fragment 60 vivo toxicology 60 NEUGENE 60 topical gel formulation 60 BEMA Granisetron 60 ZK EPO 60 MYDICAR ® 60 RhuDex R 60 Phase 2a Study 60 class mGluR5 inhibitor 60 vascular disrupting agent 60 http:/www.sangamo.com 60 lucinactant 60 Presents Positive Preclinical 60 elacytarabine 60 UVIDEM 60 BrachySil TM 60 Triolex 60 novel nucleoside analog 60 R# #mg BID 60 Submits Biologics License Application 60 induced tumor regression 60 riociguat 60 metabolite identification 60 Tarvacin TM 60 Randomized Phase II 60 please visit http:/www.atherogenics.com 60 clinical trials dacetuzumab SGN 60 protein tyrosine phosphatase 1B 60 NPC 1C 60 clinical trials SGN 60 TRACON Pharmaceuticals 60 Amigal TM 60 Therapeutic Competitors Companies 60 novel peptide 60 Nasdaq IDRA 60 antiangiogenesis therapies 60 relapsed MM 60 Receives Orphan Drug 60 PrevOnco ™ 60 MSCRAMM R 60 investigational monoclonal antibody 60 Urocortin 2 60 budesonide MMX Phase III 60 peptidic compound 60 Phase 1b Clinical Trial 60 Prochymal TM 60 nanopharmaceutical 60 TELINTRA 60 PRX # 60 testing huN# DM1 60 development peramivir neuraminidase 60 AeroLEF TM 60 Aflibercept 60 HCV protease inhibitor 60 Rigel R# 60 advanced carcinoid 60 mecarbil 60 evaluating picoplatin 60 tezampanel 60 epothilone 60 AN# novel 60 ANYARA 60 initiate Phase 2b 60 trivalent seasonal influenza 60 proprietary PEGylation 60 initiate Phase 1b 60 HIV integrase inhibitors 60 please visit www.middlebrookpharma.com 60 RESTORE CLI trial 60 histone deacetylase HDAC inhibitor 60 targeted anticancer biopharmaceuticals 60 estrogen receptor beta agonist 60 Initiates Phase 2b 60 PF # [002] 60 dextofisopam 60 telomerase inhibitor 60 ADCC enhanced 60 Phase 2a trial 60 phosphatidylserine PS targeting 60 indibulin 60 MSCRAMM ® 60 vaginally administered lidocaine 60 nalbuphine ER 60 initiated Phase 1b 60 Phase 2b clinical trials 60 oral NKTR 60 5 HT2A inverse 60 NADiA ProsVue 60 triggers apoptosis programmed 60 GetGoal Phase III 60 serious systemic Staphylococcal 60 novel synthetic PEGylated 60 Triapine R 60 Announces Poster Presentations 60 Guanilib 60 DAC HYP 60 Inc. Nasdaq IMGN 60 candidate MyVax 60 BENLYSTA TM 60 HIV AIDS neuropathic pain 60 PREOS R 60 #/#/# Cytokinetics Incorporated 60 Phase IIIb clinical 60 MOZOBIL 60 NYSE Amex PBTH 60 targeted alpha folate 60 complete disclaimer appearshere 60 Submits NDA 60 NASDAQ SNTA 60 Patient Enrollment 60 Shigamabs R 60 EDEMA4 60 solanezumab 60 Correspondent Liverpool Echo 60 microsurgical disciplines 60 monoclonal antibody biologic 60 Pruvel ™ 60 Sym# 60 BEMA ® 60 platform HDL Mimetic 60 QNEXA ® 60 phase Ib clinical 60 Alzheimer disease cognitive impairment 60 Receives Milestone Payment 60 Tyrosine Kinase Inhibitor 60 visit www.sciclone.com 60 TRANSDUR ® 60 EVIZON TM squalamine lactate 60 OncoVEX GM CSF 60 Prednisporin 60 read Palintologist 60 Antibody Drug Conjugate 60 world safest multivalent 60 secretory phospholipase A2 sPLA2 60 oral talactoferrin 60 Besivance 60 Pentad TM 60 Ceflatonin R 60 Zoraxel 60 Affilin ® 60 apoptosis inducer 60 INxin TM 60 HIV maturation inhibition 60 LEUKINE 60 Cintredekin Besudotox 60 ALN VSP Phase 60 CDK cyclin dependent 60 OncoVEX 60 radezolid 60 Nasdaq FOLD 60 RiVax 60 Nventa proprietary CoVal 60 Onco TCS 60 Phase 2b MATRIX 60 Lauren Silvernail 60 thetreatment 60 Thiovir 60 BRIM2 60 candidates Dyloject TM 60 IIa trial 60 incyclinide 60 Zemplar Capsules 60 selective inverse agonist 60 CMV vaccine 60 Telatinib 60 Proellex TM 60 Soliris eculizumab 60 NABTT 60 phase IIb trial 60 ICA # 60 Kamada AAT 60 velafermin 60 BCX# 60 Cardium Therapeutics TM 60 HuCNS SC ® 60 Solazed ™ 60 AVN# Phase 60 Aryplase 60 epothilones 60 Entereg TM 59 H#N# VLP vaccine 59 Nanobody 59 OTC BB PVCT 59 hoFH 59 EZN 59 nonclinical studies 59 allosteric modulator NAM 59 CINQUIL 59 ritonavir boosted danoprevir 59 ELACYT 59 Aplidin 59 OTCBB HXBM developer 59 highly selective inhibitor 59 acyclovir Lauriad ® 59 MGN# 59 Nexavar ® 59 Inc. Nasdaq TNGN 59 MEND CABG 59 Luramist TM 59 oncolytic vaccine 59 Maxy G# 59 trodusquemine 59 OMNARIS HFA 59 Phase #/#a 59 antiinfective products 59 DermaVir 59 bavituximab monotherapy trial 59 evaluating satraplatin plus 59 PRTX 59 IV RSD# 59 Cand5 59 MET amplification 59 ATL# [001] 59 CYP#A# CYP#D# 59 proteasome inhibitor 59 NicVAX TM 59 TLR7 agonist 59 zanolimumab 59 volociximab 59 selective modulator 59 Vaxfectin TM formulated 59 pharmacological chaperone 59 rusalatide acetate 59 Azixa 59 Aganocide R 59 immuno therapeutic 59 Cleviprex TM clevidipine 59 unique alkylating agent 59 CYC# 59 novel topoisomerase 59 CK # novel 59 Albuferon Phase 59 Dacogen injection 59 enhance ApoA 59 OncoVex 59 Receives Fast Track 59 adhesion molecule EpCAM expressing 59 Initiated Phase 59 cosmetic cosmeceutical products 59 CTA# Injection 59 Civacir 59 KRN# 59 Hepatitis C Virus HCV 59 topically applied SEPA 59 TEMSO 59 Universal Pandemic Influenza 59 FUSILEV ® 59 demonstrated antitumor activity 59 TRANSDUR Bupivacaine 59 confirmatory pivotal 59 OMNARIS Nasal Spray 59 rheumatoid arthritis thrombocytopenia 59 Eg5 kinesin spindle 59 oral Hsp# inhibitor 59 www.telik.com 59 REGN# 59 APTIMA HPV assay 59 Valortim TM 59 Behcet uveitis 59 ostarine 59 Drug Candidate 59 SPL# Gel vaginal microbicide 59 oral Azacitidine 59 PTH analogue 59 VIVITROL ® 59 Phase Ib Clinical Trial 59 anti CD3 monoclonal 59 ALN HPN 59 initiate Phase IIb 59 Dose Escalation 59 dependent kinase inhibitor 59 Tarceva TM 59 rumpled dresser 59 Tezampanel 59 generation HCV protease 59 Epothilones 59 Onalta 59 ruxolitinib 59 JAK inhibitor 59 forodesine HCl 59 RNAi therapeutic targeting 59 HCV nucleoside polymerase inhibitors 59 Matrix Phase 2b 59 Fodosine 59 exploratory Phase IIa 59 Visit www.BASInc.com 59 VITAL Trial 59 mda 7 59 fosbretabulin 59 Ultrafast Insulin 59 immunotherapeutic agent 59 Inc. AMEX YMI 59 integrin inhibitor 59 orally bioavailable 59 Androxal ® 59 OHR/AVR# 59 CG# [003] 59 GTC recombinant human 59 compound AEZS 59 tests miRview TM 59 intranasal insulin product 59 sulfonylhydrazine class 59 Receives Orphan Drug Designation 59 Phase III confirmatory 59 Dapagliflozin 59 targets Galectin receptors 59 CCR5 receptor antagonist 59 PMX # antibiotic 59 biomimetics non 59 alpha folate receptor 59 seeking quali MORE 59 Sulonex TM 59 Urocidin TM 59 LentiVector technology 59 multi kinase inhibitor 59 vivo glucose 59 Traficet EN 59 Thiarabine 59 Loramyc TM 59 OTCBB PYTO 59 EDEMA3 trial 59 Therapeutic Vaccine 59 CIMZIA ™ 59 Nasulin TM 59 KRYSTEXXA TM pegloticase 59 MVA MUC1 IL2